A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma
Ocular Hypertension

Interventions

DRUG: INO-8875
DRUG: Placebo

Sponsor

Inotek Pharmaceuticals Corporation